April 17, 2025 a 04:01 pm
ABT: Fundamental Ratio Analysis - Abbott Laboratories
Abbott Laboratories, a leader in the healthcare sector, continues to demonstrate solid performance across its diverse segments. The company's dedication to innovation and expansion in diagnostics and medical devices highlights its potential for continued growth. With a robust historical presence, Abbott represents a stable investment opportunity.
Fundamental Rating
The current data reveals a stable fundamental performance for Abbott Laboratories. The ratings across several important financial metrics indicate a consistent and reliable business model.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
Historical Rating
The historical scores show consistency in Abbott's financial health, affirming investor confidence over time.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-16 | 3 | 4 | 5 | 5 | 1 | 2 | 2 |
| - | 0 | 4 | 5 | 5 | 1 | 2 | 2 |
Analyst Price Targets
Analyst targets suggest moderate growth potential, reflecting cautious optimism in the current market conditions.
| High | Low | Median | Consensus |
|---|---|---|---|
| $140 | $135 | $137.5 | $137.5 |
Analyst Sentiment
Analysts maintain a positive outlook, with a majority recommending a 'Buy' for Abbott Laboratories stock.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 27 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Abbott Laboratories exhibits a strong market presence with significant potential for growth in the healthcare sector. The company's financial health is bolstered by consistent earnings and strategic innovations. While the stock prices might reflect market volatility, its strong fundamentals offer a buffer. However, investors should remain vigilant to sector-specific risks. With a consensus recommendation of Buy, investors may consider adding Abbott to their portfolios.